A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

March 13, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatitis CKidney Transplant; ComplicationsHeart Transplant Infection

Interventions

DRUG

Mavyret

Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients

Trial Locations (1)

Mayo Clinic in Arizona, Phoenix